HYPD Stock Analysis: Buy, Sell, or Hold?

HYPD - Hyperion DeFi, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$3.18
0.04 (1.27%) ▲
5d: +16.91%
30d: +20.45%
90d: -18.46%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026 0d

Get Alerted When HYPD Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 MIXED SIGNALS: HYPD shows conflicting indicators. Wait for confirmation before entering.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$2.65
Based on -19.6% avg growth
INTRINSIC VALUE TODAY
$1.64
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.6x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: HYPD is currently trading at $3.18, which is considered extended relative to its 30-day fair value range of $2.55 to $2.94. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.4) compared to its historical average (6.6). Remarkably, the market is currently pricing in an annual earnings decline of 28.7% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, HYPD is in a downtrend. Immediate support is located at $2.56, while resistance sits at $3.57.

Market Sentiment: HYPD scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.20 (+126.4%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $2.55 - $2.94
Company Quality Score 38/100 (SELL)
Volume Confirmation HIGH
Confidence Score 23.8%

All Signals

  • BEARISH: Price extended above range (+8.2% above its trading range)
  • BEARISH: Weak technical setup (15/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 126.4% below Wall St target ($7.20)
  • WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $2.55 - $2.94
Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $2.56
Resistance Level $3.57
Current Trend Downtrend
Technical data as of Aug 21, 2026

Fundamental Context

Forward P/E (Next Year Est.) 2.38
Wall Street Target $7.20 (+126.4%)
Revenue Growth (YoY) 1559.5%
Profit Margin 474.9%
Valuation Discount vs History -28.7% cheaper
PE vs Historical 2.4 vs 6.6 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -28.7% (market-implied from PE analysis)
1-Year Target $2.86 (-10%)
2-Year Target $2.58 (-19%)
3-Year Target $2.32 (-27%)
3-Yr Target (if PE normalizes) (PE: 2→7) $6.42 (+102%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 20.1, Growth: -43.2%) $19.53 (+514%)
Base: (SPY PE: 2.4, Growth: -43.2%) $2.32 (-27%)
Bear: (PE: 2.0, Growth: -43.2%) $1.97 (-38%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.4 to 6.6
Stabilization Target: $8.81 (+177.1%)
PE Expansion Potential: +177.1%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: August 24, 2026 7:19 AM ET
Data refreshes hourly during market hours. Next update: 8:19 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for HYPD.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
CYTK
Cytokinetics Inc
STRONG BUY
21 analysts
$110 66 BUY
INSM
Insmed Inc
STRONG BUY
21 analysts
$200 41 HOLD
CRSP
Crispr Therapeutics AG
BUY
28 analysts
$88 41 HOLD
BHVN
Biohaven Ltd.
STRONG BUY
16 analysts
$23 49 HOLD
CRNX
Crinetics Pharmaceutical…
STRONG BUY
17 analysts
$86 40 SELL

More Analysis for HYPD

HYPD Technical Chart HYPD Price Prediction HYPD Earnings Date HYPD Investment Advisor HYPD Fair Price Analyzer HYPD Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals